An oncology expert explains how clinical and non-clinical evidence impact the clinical pathway decision-making for patients with NSCLC. Edward Arrowsmith, MD: We have a couple ways that we're tracking ...

"What has been missing is the patient's perspective," says one industry consultant. The future of clinical pathways is patient-centric: an approach that balances the long-standing focus on ...

Click here to view video highlights from this interview. AJMC ®: Kaiser Permanente has set up a clinical pathway for the use of SGLT2 [sodium-glucose cotransporter-2] inhibitors for patients with ...

During the pandemic, the Centers for Medicare & Medicaid Services (CMS) gave Oncology Care Model (OCM) practices the opportunity to "forgo upside and downside risk for performance periods" and floated ...

Expert faculties (domain specific experts in clinical, technical and analytical areas) for clinical audits and registries work closely with multidisciplinary clinical groups and patients. This faculty ...

In the realm of oncology, the advent of clinical pathways has gained substantial traction in the past two decades as the increasing cost and complexity of cancer care demanded structured, ...

Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) Next-generation sequencing (NGS) is ...

Pasithea Therapeutics Corp. has announced the successful enrollment and initial dosing of three subjects in Cohort 6 of its Phase 1 clinical trial for PAS-004, a candidate for treating ...

Please provide your email address to receive an email when new articles are posted on . Hospitalizations with vs. without pathway use were shorter and cost less. Significantly more ...